Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioVascular: Platelet mediation

Preventing vascular graft failure by pharmaceutical means is not an area that has seen much success, but BioVascular Inc. hopes its saratin can prevent the buildup of platelets inside blood vessels that often causes graft failure. The company expects interim data from a pair of European Phase I/II trials next year.

Saratin is a recombinant version of a 12-kD polypeptide derived from leech saliva that helps keep the blood vessel open after

Read the full 711 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE